NC
GILD icon

North Capital’s Gilead Sciences GILD Stock Holding History

North Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$262K Hold
2,076
– – 0.2% 78
2026
Q1 		$289K Sell
2,076
-3
-0.1% -$420 0.25% 64
2025
Q4 		$255K Sell
2,079
-1
-0% -$122 0.22% 72
2025
Q3 		$231K Buy
2,080
+51
+3% +$5.8K 0.18% 68
2025
Q2 		$225K Sell
2,029
-172
-8% -$18.3K 0.19% 70
2025
Q1 		$247K Buy
+2,201
New +$227K 0.23% 60

Other funds holding GILD

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

North Capital's GILD Position: Q2 2026 in Review

North Capital held its Gilead Sciences (GILD) position steady in Q2 2026 at 2,076 shares worth $262K. The position accounts for 0.2% of the portfolio, ranked #78.

North Capital first reported a position in GILD in Q1 2025 and has held it in 6 quarters since. The position peaked at $289K in Q1 2026. 690 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • North Capital held 2,076 shares of Gilead Sciences worth $262K as of Q2 2026.
  • North Capital left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up 0.2% of North Capital's portfolio in Q2 2026, its #78 holding.
  • North Capital first reported a position in Gilead Sciences in Q1 2025 and has held it in 6 quarters since.
  • North Capital's Gilead Sciences position peaked at $289K in Q1 2026.
  • 690 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on North Capital's 13F filing for Q2 2026, filed 14 Jul 2026.